Drug Profile
Recombinant human pulmonary surfactant protein-B - AzarGen Biotechnologies
Alternative Names: rh-SPB - AzarGen BiotechnologiesLatest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator AzarGen Biotechnologies
- Class Plant proteins; Pulmonary surfactant associated proteins
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neonatal respiratory distress syndrome
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Neonatal-respiratory-distress-syndrome in South Africa
- 25 Jul 2017 AzarGen Biotechnologies has patent protection for method of production of human pulmonary surfactant protein-B in Europe
- 29 Sep 2016 AzarGen Biotechnologies and iBio Inc. enter into a commercial developemnt agreement for surfactant protein for Neonatal respiratory distress syndrome before September 2016